Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. · 2009
Read Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. by Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2731764.txt.
Introduction
Henderson and co-authors tested in 2009 AC-1202, a ketogenic compound taken by mouth, in a ninety-day trial for mild to moderate Alzheimer's disease. Brains in Alzheimer's use glucose poorly in specific regions early on. Ketone bodies, made when glucose is scarce, offer the brain an alternate fuel that it can still burn.
In one hundred fifty-two patients on normal diets and usual Alzheimer's drugs, the compound raised a blood ketone marker within hours. Thinking scores favored the compound over placebo at day forty-five in all analysis groups. Among patients without the APOE4 risk gene form, the benefit was larger and still present at day ninety. A stronger ketone response also tracked with better scores.
Catalog record
| CREATOR | Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial By Samuel T Henderson, Janet L Vogel, Linda J Barr, Fiona Garvin, Julie J Jones, Lauren C Costantini Published in: Nutrition & Metabolism DOI: 10.1186/1743-7075-6-31 ABSTRACT Background Alzheimer's disease (AD) is characterized by early and region-specific declines in cerebral glucose metabolism. Ketone bodies are produced by the body during glucose deprivation and are metabolized by the brain. An oral ketogenic compound, AC-1202, was tested in subjects with probable AD to examine if ketosis could improve cognitive performance. Methods Daily administration of AC-1202 was evaluated in 152 subjects diagnosed with mild to moderate AD in a US-based, 90-day, randomized, double-blind, placebo-controlled, parallel-group study. Subjects were on a normal diet and continued taking approved AD medications. Primary cognitive end points were mean change from Baseline in the AD Assessment Scale-Cognitive subscale (ADAS-Cog), and global scores in the AD Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC). AC-1202 was compared to Placebo in several population groups, including: intention-to-treat (ITT), per protocol, and dosage compliant groups. Results were also stratified by APOE4 carriage status (a predefined analysis based on the epsilon 4 (E4) variant of the apolipoprotein E gene). This trial was registered with ClinicalTrials.gov, registry number NCT00142805, information available at Results AC-1202 significantly elevated a serum ketone body (β-hydroxybutyrate) 2 hours after administration when compared to Placebo. In each of the population groups, a significant difference was found between AC-1202 and Placebo in mean change from Baseline in ADAS-Cog score on Day 45: 1.9 point difference, p = 0.0235 in ITT; 2.53 point difference, p = 0.0324 in per protocol; 2.6 point difference, p = 0.0215 in dosage compliant. Among participants who did not carry the APOE4 allele (E4(-)), a significant difference was found between AC-1202 and Placebo in mean change from Baseline in ADAS-Cog score on Day 45 and Day 90. In the ITT population, E4(-) participants (N = 55) administered AC-1202 had a significant 4.77 point difference in mean change from Baseline in ADAS-Cog scores at Day 45 (p = 0.0005) and a 3.36 point difference at Day 90 (p = 0.0148) compared to Placebo. In the per protocol population, E4(-) participants receiving AC-1202 (N = 37) differed from placebo by 5.73 points at Day 45 (p = 0.0027) and by 4.39 points at Day 90 (p = 0.0143). In the dosage compliant population, E4(-) participants receiving AC-1202 differed from placebo by 6.26 points at Day 45 (p = 0.0011, N = 38) and 5.33 points at Day 90 (p = 0.0063, N = 35). Furthermore, a significant pharmacologic response was observed between serum β-hydroxybutyrate levels and change in ADAS-Cog scores in E4(-) subjects at Day 90 (p = 0.008). Adverse events occurred more frequently in AC-1202 subjects, were primarily restricted to the gastrointestinal system, and were mainly mild to moderate in severity and transient in nature. Conclusion AC-1202 rapidly elevated serum ketone bodies in AD patients and resulted in significant differences in ADAS-Cog scores compared to the Placebo. Effects were most notable in APOE4(-) subjects who were dosage compliant. BACKGROUND Alzheimer's disease (AD) is a common, age-associated, progressive, neurodegenerative disease. Risk of developing the most common form of AD (sporadic or late onset) is principally linked to age, and the carriage status of the epsilon 4 (E4) variant of the apolipoprotein E gene (APOE). APOE4 behaves in a dominant, dose-dependent manner; a single copy increases risk of developing AD approximately 3 fold, while two copies increases risk approximately 10 fold (for review of APOE see [1]). Clinically, AD is characterized by progressive decline in memory and language, and pathologically by accumulation of senile plaques and neurofibrillar tangles. Another prominent feature of AD is regional cerebral hypometabolism. Early imaging studies revealed low cerebral metabolic rates of glucose use (CMRglu) in subjects with probable AD [2], and this is now recognized as a general feature of the disease [3]. The most commonly affected areas include the posterior cingulate, parietal, temporal and prefrontal regions [4]. These deficits can be detected in pre-symptomatic, at risk individuals, such as E4 carriers, as young adults. Such changes have been detected in cognitively normal subjects well before there is widespread neuronal loss or predicted plaque deposition, suggesting that low CMRglu is an early event in the disease [5]. The cause of the hypometabolism remains unclear and may be due to loss of neurons or dendritic fields. Alternatively, hypometabolism has been attributed to the action of AD-specific factors. Amyloid beta (Aβ) [6] and fragmentation of the ApoE4 protein [7] have both been implicated in dys-regulation of mitochondrial function. In addition, several authors have proposed changes in insulin signaling as a potential contributor to the development of hypometabolism [8-12]. Regardless of its cause, therapies aimed at correcting cellular metabolism may prove beneficial to the AD patient [13]. One such promising therapy is the induction of ketosis (for overview see [14]). Under normal circumstances, the main energy substrate for the brain is glucose. However, under certain situations, such as extended fasting, the liver will produce ketone bodies for use by extrahepatic tissues, including the brain. Three compounds are normally considered ketone bodies: β-hydroxybutyrate (BHB), acetoacetate (ACA) and acetone. Ketone bodies are an efficient fuel for cells [15,16]. Levels of circulating ketone bodies can be raised by adherence to a low-carbohydrate, high-fat, ketogenic diet. Ketogenic diets have been used extensively for the reduction of seizure frequency in children with refractive epilepsy [17] and have gained interest in several other neurological conditions, including amyotrophic lateral sclerosis [18], traumatic brain injury [19] and ischemia [20] (for review see [14,21,22]). In addition, several preclinical studies have suggested that induced ketosis may be beneficial in AD. For example, the toxic effects of the Aβ peptide in cultured neurons were shown to be mitigated by incubating the cells with BHB [23]. Also, a ketogenic diet reduced total Aβ40 and Aβ42 in a transgenic mouse model of AD after 38 days of feeding [24]. Alzheimer's disease patients frequently undergo changes in food preference toward sweet, carbohydrate-rich foods [25-27], which would make compliance to a ketogenic diet difficult. Therefore, AC-1202, a form of medium chain triglycerides (MCTs), was developed to safely elevate serum ketone bodies even in the presence of carbohydrate in the diet. MCTs were chosen for this study due to their safety profile [28], and long historical use in lipid malabsorption disorders and ketogenic diets [29]. Due to the unique physical properties of AC-1202, it is metabolized differently from the more common long chain triglycerides (LCT) [30]. If sufficient amounts of AC-1202 are consumed, a mild state of ketosis can be induced without modification of the diet. In a pilot study of mild to moderate AD patients, induction of ketosis by AC-1202 rapidly improved cognitive performance in subjects lacking the APOE4 allele [31]. The primary aim of the present study was to assess whether daily dosing of AC-1202 in mild to moderate AD subjects would improve cognitive performance as measured by change from Baseline in the AD Assessment Scale-Cognitive subscale (ADAS-Cog), and global score in the AD Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC) after 90 days. Additional outcomes investigated included how cognitive scores were